Literature DB >> 3606081

Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum.

R N Jones, A L Barry.   

Abstract

Eighty-seven organisms were tested against ceftriaxone, cefotaxime, desacetylcefotaxime, and the combination of cefotaxime and desacetylcefotaxime (1:1 ratio) in broth containing 0, 25, or 50% human serum. In the presence of human serum, ceftriaxone MICs were four- to eightfold higher than those obtained in broth, changing 98% of Staphylococcus aureus strains from the susceptible to the moderately susceptible category and 53% of selected gram-negative strains to a more resistant category. The MICs of cefotaxime, desacetylcefotaxime, and cefotaxime plus desacetylcefotaxime were not adversely affected by human serum; in fact, the bactericidal activity was slightly improved.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606081      PMCID: PMC174842          DOI: 10.1128/AAC.31.5.818

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Comparative pharmacokinetics of cefoperazone and cefotaxime.

Authors:  H Lode; B Kemmerich; P Koeppe; D Belmega; H Jendroschek
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

2.  Effects of cefotaxime and cefodizime on human granulocyte functions in vitro.

Authors:  M T Labro; C Babin-Chevaye; J Hakim
Journal:  J Antimicrob Chemother       Date:  1986-08       Impact factor: 5.790

3.  The influence of protein binding on the antistaphylococcal activity of antibiotics.

Authors:  R H George
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

4.  Clinical pharmacology of the new penicillins. 1. The importance of serum protein binding in determining antimicrobial activity and concentration in serum.

Authors:  C M Kunin
Journal:  Clin Pharmacol Ther       Date:  1966 Mar-Apr       Impact factor: 6.875

5.  Serum protein binding and extravascular distribution of antimicrobials.

Authors:  D N Gerding; L R Peterson
Journal:  J Antimicrob Chemother       Date:  1985-02       Impact factor: 5.790

6.  Protein binding of beta-lactams: the effects on activity and pharmacology particularly tissue penetration. I.

Authors:  R Wise
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

7.  Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalis.

Authors:  D F Sahm; C N Baker; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

Review 8.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

9.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

10.  Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

Authors:  J M Trang; R F Jacobs; G L Kearns; A L Brown; T G Wells; F L Underwood; R B Kluza
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

View more
  21 in total

1.  Effect of ertapenem protein binding on killing of bacteria.

Authors:  David E Nix; Kathryn R Matthias; Emily C Ferguson
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin.

Authors:  S K Nath; G A Foster; L A Mandell; C Rotstein
Journal:  Can J Infect Dis       Date:  1995-01

3.  Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.

Authors:  G G Zhanel; I D Kirkpatrick; D J Hoban; A M Kabani; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  N-terminally modified linear and branched spermine backbone dipeptidomimetics against planktonic and sessile methicillin-resistant Staphylococcus aureus.

Authors:  Rikeshwer Prasad Dewangan; Seema Joshi; Shalini Kumari; Hemlata Gautam; Mohammed Shahar Yar; Santosh Pasha
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

5.  Disrupting Gram-Negative Bacterial Outer Membrane Biosynthesis through Inhibition of the Lipopolysaccharide Transporter MsbA.

Authors:  Mary Kate Alexander; Anh Miu; Angela Oh; Mike Reichelt; Hoangdung Ho; Cecile Chalouni; Sharada Labadie; Lan Wang; Jun Liang; Nicholas N Nickerson; Huiyong Hu; Lan Yu; Miaofen Du; Donghong Yan; Summer Park; Janice Kim; Min Xu; Benjamin D Sellers; Hans E Purkey; Nicholas J Skelton; Michael F T Koehler; Jian Payandeh; Vishal Verma; Yiming Xu; Christopher M Koth; Mireille Nishiyama
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 6.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

7.  Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.

Authors:  D E Nix; J H Wilton; J Hyatt; J Thomas; L C Strenkoski-Nix; A Forrest; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 8.  The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.

Authors:  R N Jones
Journal:  Infection       Date:  1994       Impact factor: 3.553

9.  Antibacterial activity of resazurin-based compounds against Neisseria gonorrhoeae in vitro and in vivo.

Authors:  Deanna M Schmitt; Kristie L Connolly; Ann E Jerse; Melinda S Detrick; Joseph Horzempa
Journal:  Int J Antimicrob Agents       Date:  2016-07-19       Impact factor: 5.283

Review 10.  Efficacy and safety of cefotaxime in the management of pediatric infections.

Authors:  R F Jacobs
Journal:  Infection       Date:  1991       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.